methyl 2-[2-(tert-butoxycarbonylamino)ethoxy]-4-methoxybenzoate | 402933-40-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 2-[2-(tert-butoxycarbonylamino)ethoxy]-4-methoxybenzoate
• 英文别名: methyl 4-methoxy-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]benzoate
• CAS: 402933-40-8
• 化学式: C₁₆H₂₃NO₆
• 分子量: 325.362
• InChiKey: BZWPXVRAFJIXPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 2-[2-(tert-butoxycarbonylamino)ethoxy]-4-methoxybenzoate 在 吡啶 、 lithium aluminium tetrahydride 、 四(三苯基膦)钯 、 palladium 10% on activated carbon 、 氢溴酸 、 氢气 、 potassium carbonate 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 110.0 ℃ 、101.33 kPa 条件下， 反应 98.5h， 生成 1,1-dimethylethyl 8-cyano-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate
  参考文献：
  名称：

  Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles

  摘要：

  The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P(1) receptors, while a variety of side effects have been ascribed to its S1P(3) receptor activity. Although S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, a variety of chemotypes have been found to show S1P(1) receptor agonism. Here we describe a study of the tolerance of the S1P(1) and S1P(3) receptors toward bicyclic heterocycles of systematically varied shape and connectivity incorporating acidic, basic, or zwitterionic headgroups. We compare their physicochemical properties, their performance in in vitro and in vivo pharmacokinetic models, and their efficacy in peripheral lymphocyte lowering. The campaign resulted in the identification of several potent S1P(1) receptor agonists with good selectivity vs S1P(3) receptors, efficacy at <1 mg/kg oral doses, and developability properties suitable for progression into preclinical development.

  DOI：

  10.1021/jm5010336
• 作为产物：
  描述：

  N-Boc-溴乙胺 在 potassium carbonate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以81%的产率得到methyl 2-[2-(tert-butoxycarbonylamino)ethoxy]-4-methoxybenzoate
  参考文献：
  名称：

  WO2006/57868

  摘要：

  公开号：

文献信息

• AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS
  申请人：Argade Ankush Baburao

  公开号：US20090227566A1

  公开（公告）日：2009-09-10

  This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound or prodrug thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor. An example of a compound of formula (I) is (a).

  本发明涉及公式(I)的化合物(或其药学上可接受的盐或前药)、其制药组合物以及其作为Xa因子和/或凝血酶抑制剂的用途，以及其制备过程和中间体。公式(I)的化合物的一个例子是(a)。
• Antithrombotic Diamides
  申请人：Franciskovich Jeffry Bernard

  公开号：US20090062271A1

  公开（公告）日：2009-03-05

  This application relates to a compound of formula I (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

  本申请涉及公式I化合物（或其药学上可接受的盐），其制药组合物，以及其作为Xa因子和/或凝血酶抑制剂的用途，以及其制备过程和中间体。
• Antithrombotic diamides
  申请人：Eli Lilly and Company

  公开号：US07666866B2

  公开（公告）日：2010-02-23

  This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt of the compound) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa and/or thrombin, as well as a process for its preparation and intermediates therefor.

  本发明涉及公式（I）的化合物（或该化合物的药学上可接受的盐），其制药组合物，以及其作为因子Xa和/或凝血酶的抑制剂的用途，以及其制备方法和中间体。
• ANTITHROMBOTIC DIAMIDES
  申请人：ELI LILLY AND COMPANY

  公开号：EP1819693A1

  公开（公告）日：2007-08-22
• US7666866B2
  申请人：——

  公开号：US7666866B2

  公开（公告）日：2010-02-23